LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 4460

Search options

  1. Article ; Online: Question: How Should I Monitor and Adjust the Clozapine Dose for My Patients Who Develop COVID and Could Benefit From Nirmatrelvir/Ritonavir?

    de Leon, Jose

    Journal of clinical psychopharmacology

    2024  Volume 44, Issue 2, Page(s) 201–203

    MeSH term(s) Humans ; Ritonavir ; Clozapine/adverse effects ; COVID-19 ; COVID-19 Drug Treatment ; Lactams ; Leucine ; Nitriles ; Proline
    Chemical Substances nirmatrelvir (7R9A5P7H32) ; Ritonavir (O3J8G9O825) ; Clozapine (J60AR2IKIC) ; Lactams ; Leucine (GMW67QNF9C) ; Nitriles ; Proline (9DLQ4CIU6V)
    Language English
    Publishing date 2024-02-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604631-9
    ISSN 1533-712X ; 0271-0749
    ISSN (online) 1533-712X
    ISSN 0271-0749
    DOI 10.1097/JCP.0000000000001828
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Promoting safer and wider worldwide use of clozapine.

    de Leon, Jose

    Schizophrenia research

    2024  

    Abstract: This issue focuses on the past, the present and the future of clozapine. Of the 43 clozapine articles, nine are historical articles dealing with the past, 29 deal with the present and five with laboratory assays which may influence its future use. These ... ...

    Abstract This issue focuses on the past, the present and the future of clozapine. Of the 43 clozapine articles, nine are historical articles dealing with the past, 29 deal with the present and five with laboratory assays which may influence its future use. These 43 articles include 219 different authors from 56 countries/regions and five continents.
    Language English
    Publishing date 2024-03-22
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 639422-x
    ISSN 1573-2509 ; 0920-9964
    ISSN (online) 1573-2509
    ISSN 0920-9964
    DOI 10.1016/j.schres.2024.03.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Can Slow Personalized Titration Using C-Reactive Protein Monitoring Decrease the High Rates and Mortality of Clozapine-Associated Myocarditis Seen in Some Countries? A Call for Research.

    de Leon, Jose

    Journal of clinical psychopharmacology

    2024  Volume 44, Issue 3, Page(s) 212–219

    Abstract: Purpose/background: The hypothesis that slower personalized titration may prevent clozapine-associated myocarditis and decrease the disproportion incidence of 3% found in Australia was not described in a recent Australian article in this journal.: ... ...

    Abstract Purpose/background: The hypothesis that slower personalized titration may prevent clozapine-associated myocarditis and decrease the disproportion incidence of 3% found in Australia was not described in a recent Australian article in this journal.
    Methods: Six countries in addition to Australia have published information suggesting a similar incidence of clozapine-associated myocarditis. On September 19, 2023, PubMed searches were updated for articles from the United States, Korea, Japan, Canada, New Zealand, and Turkey.
    Findings/results: An incidence of 3.5% (4/76) was found in a US hospital, but US experts were the first to propose that clozapine-associated myocarditis may be a hypersensitivity reaction associated with rapid titration and possibly preventable. Koreans and Japanese are of Asian ancestry and need lower minimum therapeutic doses for clozapine than patients of European ancestry. A 0.1% (2/1408) incidence of myocarditis during clozapine titration was found in a Korean hospital, but pneumonia incidence was 3.7% (52/1408). In 7 Japanese hospitals, 34% (37/110) of cases of clozapine-associated inflammation were found during faster titrations (based on the official Japanese titration) versus 13% (17/131) during slower titrations (based on the international titration guideline for average Asian patients). Recent limited studies from Canada, New Zealand, and Turkey suggest that slower personalized titration considering ancestry may help prevent clozapine-associated myocarditis.
    Implications/conclusions: Other countries have very limited published data on clozapine-associated myocarditis. Based on a recent Australian case series and these non-Australian studies, the author proposes that Australia (and other countries) should use slow personalized titration for clozapine based on ancestry and c-reactive protein monitoring.
    MeSH term(s) Humans ; Clozapine/adverse effects ; Clozapine/administration & dosage ; Myocarditis/chemically induced ; Myocarditis/epidemiology ; C-Reactive Protein/metabolism ; Antipsychotic Agents/adverse effects ; Antipsychotic Agents/administration & dosage ; Incidence ; Australia ; Canada/epidemiology ; Japan ; New Zealand/epidemiology ; United States/epidemiology ; Turkey ; Schizophrenia/drug therapy ; Drug Monitoring/methods ; Precision Medicine ; Republic of Korea
    Chemical Substances Clozapine (J60AR2IKIC) ; C-Reactive Protein (9007-41-4) ; Antipsychotic Agents
    Language English
    Publishing date 2024-03-28
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 604631-9
    ISSN 1533-712X ; 0271-0749
    ISSN (online) 1533-712X
    ISSN 0271-0749
    DOI 10.1097/JCP.0000000000001843
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Book: A practitioner's guide to prescribing antiepileptics and mood stabilizers for adults with intellectual disabilities

    De Leon, Jose

    2012  

    Author's details Jose de Leon, ed
    Keywords Anticonvulsants--Therapeutic use. ; Drugs--Prescribing ; People with mental disabilities--Medical care
    Subject code 615.7840874
    Language English
    Size XXXI, 507 S. : Ill., 24 cm
    Publisher Springer
    Publishing place New York u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT017185594
    ISBN 978-1-4614-2011-8 ; 1-4614-2011-3 ; 9781461420125 ; 1461420121
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  5. Article: An international clozapine titration guideline for clozapine: An opportunity for moving forward on personalizing clozapine treatment in India and other countries.

    de Leon, Jose

    Indian journal of psychiatry

    2022  Volume 64, Issue 4, Page(s) 331–334

    Language English
    Publishing date 2022-07-13
    Publishing country India
    Document type Editorial
    ZDB-ID 221523-8
    ISSN 0019-5545
    ISSN 0019-5545
    DOI 10.4103/indianjpsychiatry.indianjpsychiatry_423_22
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Reflections on the Lack of Consideration of Ethnic Ancestry to Stratify Clozapine Dosing.

    de Leon, Jose

    Psychiatry investigation

    2023  Volume 20, Issue 3, Page(s) 183–195

    Abstract: This review article argues against trusting standard clozapine references, including the US package insert, because they do not include advances in the sciences of pharmacokinetics and pharmacovigilance and ignore the effects of ethnic ancestry on ... ...

    Abstract This review article argues against trusting standard clozapine references, including the US package insert, because they do not include advances in the sciences of pharmacokinetics and pharmacovigilance and ignore the effects of ethnic ancestry on therapeutic dosing. The minimum therapeutic dose leading to the minimum therapeutic concentration of 350 ng/mL in serum/plasma can be used to compare individuals/groups with treatment-resistant schizophrenia. The US clozapine package insert recommends targeting doses of 300-450 mg/day and, subsequently, increments of up to 100 mg with a maximum dose of 900 mg/day. Ethnic ancestry is defined by DNA ancestry group. Asians (people with ancestry ranging from Pakistan to Japan) and Indigenous Americans are similar in clozapine dosing; their average clozapine minimum therapeutic dose ranged from 166 mg/day (female non-smokers) to 270 mg/day (male smokers). For those with European ancestry, average clozapine minimum therapeutic doses ranged from 236 mg/day (female non-smokers) to 368 mg/day (male smokers). Based on limited studies, Black (African sub-Saharan ancestry) patients may be treated with typical US doses (300-600 mg/day), assuming no poor metabolism (PM) status. Ancestry's impact on clozapine lethality in four countries is discussed (two countries with highly homogenous populations, Denmark and Japan, and two countries with increasingly heterogenous populations due to immigration, Australia and the UK). An international guideline with 104 authors from 50 countries/regions was recently published, providing 6 personalized clozapine titration schedules for adult inpatients (3 ancestry groups and PM/non-PM schedules) and recommending c-reactive protein monitoring at baseline and weekly for 4 weeks.
    Language English
    Publishing date 2023-02-28
    Publishing country Korea (South)
    Document type Journal Article
    ZDB-ID 2414364-9
    ISSN 1976-3026 ; 1738-3684
    ISSN (online) 1976-3026
    ISSN 1738-3684
    DOI 10.30773/pi.2022.0293
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The history of clozapine in clinical practice: From its introduction to a guideline proposing personalized titrations.

    de Leon, Jose

    Journal of psychopharmacology (Oxford, England)

    2022  Volume 36, Issue 6, Page(s) 657–660

    MeSH term(s) Antipsychotic Agents/adverse effects ; Clozapine/adverse effects
    Chemical Substances Antipsychotic Agents ; Clozapine (J60AR2IKIC)
    Language English
    Publishing date 2022-05-01
    Publishing country United States
    Document type Editorial
    ZDB-ID 639313-5
    ISSN 1461-7285 ; 0269-8811
    ISSN (online) 1461-7285
    ISSN 0269-8811
    DOI 10.1177/02698811221101059
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: According to the WHO clozapine pharmacovigilance database, the United Kingdom accounts for 968 fatal outcomes versus 892 in the rest of the world.

    de Leon, Jose

    British journal of clinical pharmacology

    2022  Volume 88, Issue 12, Page(s) 5434–5435

    MeSH term(s) Humans ; Clozapine/adverse effects ; Pharmacovigilance ; Antipsychotic Agents/adverse effects ; World Health Organization ; Adverse Drug Reaction Reporting Systems
    Chemical Substances Clozapine (J60AR2IKIC) ; Antipsychotic Agents
    Language English
    Publishing date 2022-09-15
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.15522
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Reflections on the Complex History of the Concept of Clozapine-Induced Inflammation during Titration.

    de Leon, Jose

    Psychiatria Danubina

    2022  Volume 34, Issue 3, Page(s) 411–421

    Abstract: Clozapine was synthesized in 1958. The Food and Drug Administration approved it in 1989 when comprehensive pharmacokinetic studies were not required and it was not known that clozapine was metabolized by the cytochrome P450 1A2 (CYP1A2). Currently it is ... ...

    Abstract Clozapine was synthesized in 1958. The Food and Drug Administration approved it in 1989 when comprehensive pharmacokinetic studies were not required and it was not known that clozapine was metabolized by the cytochrome P450 1A2 (CYP1A2). Currently it is known that clozapine personalized dosing may be influenced by one's DNA ancestry (African, European and/or Asian/Indigenous American), sex/smoking subgroup, and the presence/absence of genetic/non-genetic poor metabolizer (PM) status. The literature does not properly reflect the concept of "clozapine-induced inflammation" during rapid titration. Elaborating upon this concept, this historical review discusses: 1) clozapine-induced fever, 2) the effects of inflammation on clozapine metabolism, 3) clozapine-induced myocarditis, 4) other clozapine-induced inflammations, 4) current support for "clozapine-induced inflammation" as a hypersensitivity reaction, 5) the difficulty in addressing such a concept to a readership with diverse beliefs about it and 6) the limitations of this review in convincing skeptics. Clozapine-induced fever in the absence of any concomitant infection was first described in 1972 and is a mild form of "clozapine-induced inflammation" during rapid titration, which also includes myocarditis and other localized inflammations. They may be part of a hypersensitivity reaction that has 3 phases. In the first phase, the titration is too fast for a specific patient; either the psychiatrist was too aggressive in titrating, and/or the patient is a clozapine PM. This situation leads to a release of cytokines. In the second phase, a positive feedback loop develops; the cytokines inhibit CYP1A2, which further increases plasma clozapine concentrations. In the third phase, if the titration continues, the inflammation becomes complicated by the development of an auto-immune phenomenon leading to localized inflammation. Skeptical readers are challenged to try: 1) 6 titrations proposed for stratified dosing and 2) c-reactive protein (CRP) monitoring for personalized dosing in the absence of genetic testing for clozapine PM status.
    MeSH term(s) Humans ; Clozapine/adverse effects ; Cytochrome P-450 CYP1A2/metabolism ; Antipsychotic Agents/adverse effects ; Myocarditis/chemically induced ; C-Reactive Protein ; Inflammation/chemically induced ; Cytokines
    Chemical Substances Clozapine (J60AR2IKIC) ; Cytochrome P-450 CYP1A2 (EC 1.14.14.1) ; Antipsychotic Agents ; C-Reactive Protein (9007-41-4) ; Cytokines
    Language English
    Publishing date 2022-05-12
    Publishing country Croatia
    Document type Review ; Journal Article
    ZDB-ID 1067580-2
    ISSN 0353-5053
    ISSN 0353-5053
    DOI 10.24869/psyd.2022.411
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Precision psychiatry: The complexity of personalizing antipsychotic dosing.

    de Leon, Jose

    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

    2022  Volume 58, Page(s) 80–85

    Abstract: Recently, Salagre and Vieta commented on the complexity of implementing precision medicine in psychiatry. For 25 years, this author has focused on a circumscribed type of precision medicine: personalized dosing using pharmacokinetic mechanisms to ... ...

    Abstract Recently, Salagre and Vieta commented on the complexity of implementing precision medicine in psychiatry. For 25 years, this author has focused on a circumscribed type of precision medicine: personalized dosing using pharmacokinetic mechanisms to stratified patients. This short communication focuses on personalized dosing of three oral antipsychotics (clozapine, risperidone and paliperidone) and presents their maintenance dosing in a table which provides dose-correction factors generated by pharmacokinetic studies. Inhibitors need dose-correction factors < 1 and inducers need correction factors >1. Clozapine maintenance dosing is based on the dose needed to reach 350 ng/ml (the minimum plasma therapeutic concentration in treatment-resistant schizophrenia). Clozapine maintenance dosing is influenced by 3 levels of complexity: 1) ancestry groups (Asians/Native Americans; Europeans and Blacks), 2) sex-smoking subgroups (lowest dose in female non-smokers and highest in male smokers) and 3) presence/absence of poor metabolizer status (due to genetic and non-genetic causes including co-prescription of inhibitors, obesity or inflammation). Risperidone and paliperidone maintenance dosing are based on the dose needed to reach plasma concentrations of 20-60 ng/ml. Risperidone PMs need approximately half the dose, which can be explained by genetics (CYP2D6 PMs) or co-prescription of CYP2D6 inhibitors. Fluoxetine co-prescription may require one fourth the risperidone maintenance dose. Carbamazepine co-prescription may require twice the risperidone maintenance dose. Although not well studied, two groups may need higher doses of oral paliperidone: Koreans may need 1.5 times higher doses while those taking carbamazepine may need 3 times higher paliperidone maintenance doses. Precision dosing in psychiatry requires using blood levels of individuals.
    MeSH term(s) Antipsychotic Agents ; Benzodiazepines/therapeutic use ; Carbamazepine ; Clozapine ; Female ; Humans ; Male ; Paliperidone Palmitate/therapeutic use ; Psychiatry ; Risperidone/therapeutic use
    Chemical Substances Antipsychotic Agents ; Benzodiazepines (12794-10-4) ; Carbamazepine (33CM23913M) ; Clozapine (J60AR2IKIC) ; Risperidone (L6UH7ZF8HC) ; Paliperidone Palmitate (R8P8USM8FR)
    Language English
    Publishing date 2022-03-18
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1082947-7
    ISSN 1873-7862 ; 0924-977X
    ISSN (online) 1873-7862
    ISSN 0924-977X
    DOI 10.1016/j.euroneuro.2022.03.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top